Insulet (PODD) Capital Expenditures Growth (1y) (2011 - 2026)
Insulet (PODD) Capital Expenditures Growth (1y) (2011 - 2026) Analysis & Trends
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 198.70 Bn | 193.10 Bn | 7.27 Bn | -1.00% |
| 2 | Stryker | 125.85 Bn | 122.37 Bn | 4.50 Bn | 10.38% |
| 3 | Medtronic | 118.44 Bn | 109.22 Bn | 6.41 Bn | 6.32% |
| 4 | Boston Scientific | 72.64 Bn | 72.10 Bn | 3.85 Bn | 24.20% |
| 5 | Edwards Lifesciences | 51.94 Bn | 47.69 Bn | 1.35 Bn | 35.70% |
| 6 | Dexcom | 34.48 Bn | 32.53 Bn | 830.00 Mn | -9.99% |
| 7 | GE HealthCare Technologies | 33.60 Bn | 31.49 Bn | 2.18 Bn | 16.28% |
| 8 | Koninklijke Philips | 26.30 Bn | 22.98 Bn | 4.55 Bn | -4.32% |
| 9 | Steris | 23.00 Bn | 22.52 Bn | 684.20 Mn | -6.52% |
| 10 | Insulet | 10.18 Bn | 9.64 Bn | 562.60 Mn | 74.73% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 74.73% |
| Mar 31, 2026 | 97.56% |
| Dec 31, 2025 | 386.33% |
| Sep 30, 2025 | -79.40% |
| Jun 30, 2025 | -111.44% |
| Mar 31, 2025 | 75.71% |
| Dec 31, 2024 | -189.63% |
| Sep 30, 2024 | 233.50% |
| Jun 30, 2024 | 139.49% |
| Mar 31, 2024 | -33.33% |
| Dec 31, 2023 | 2,676.00% |
| Sep 30, 2023 | -814.29% |
| Jun 30, 2023 | 7,950.00% |
| Mar 31, 2023 | 34.62% |
| Dec 31, 2022 | -97.70% |
| Sep 30, 2022 | 105.65% |
| Jun 30, 2022 | -100.41% |
| Mar 31, 2022 | 90.24% |
| Dec 31, 2021 | 113.98% |
| Sep 30, 2021 | -287.17% |